Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abide Therapeutics Inc.

abidetx.com

Latest From Abide Therapeutics Inc.

Teva’s Austedo Fails In Tourette’s Syndrome

Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.

Clinical Trials Companies

Lundbeck Set For 'Transformative' Eptinezumab Launch

The Danish drugmaker's four 'strategic brands' – Brintellix, Abilify Maintena, Northera and Rexulti – are selling well. Now the focus is firmly on breaking into the anti-CGRP market with eptinezumab.

Sales & Earnings Neurology

Lundbeck CEO: Alder Buy Will Boost Pipeline

Deborah Dunsire tells Scrip that buying Alder offers Lundbeck a blockbuster prevention treatment for severe migraine patients, and helps rebuild Danish group’s prospects.

Deals Commercial

Lundbeck Looks To Pipeline As Generic Competition Hits

Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.

Sales & Earnings Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abide Therapeutics Inc.
  • Senior Management
  • Alan Ezekowitz, DPhil, CEO
    Kevin Finney, Pres. & COO
    Chan Beals, MD, PhD, CMO
    Gary O'Neill, PhD, CSO
  • Contact Info
  • Abide Therapeutics Inc.
    Phone: (858) 427-2590
    10835 Road to the Cure
    Ste. 250
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register